Keisuke Imafuku

Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab

Yasuhiro Fujisawa, Koji Yoshino, Atsushi Otsuka et al. · Journal of Dermatological Science · 2017 · 101 citations

Routine Blood Count, Cancer Immunosurveillance, Oncology +11

Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study

Taku Fujimura, Yota Sato, Kayo Tanita et al. · Oncotarget · 2018 · 88 citations · Full text

Loss of TRIM29 Alters Keratin Distribution to Promote Cell Invasion in Squamous Cell Carcinoma

Teruki Yanagi, Masashi Watanabe, Hiroo Hata et al. · Cancer Research · 2018 · 70 citations

Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients

Yasuhiro Fujisawa, Koji Yoshino, Atsushi Otsuka et al. · Journal of Dermatological Science · 2017 · 66 citations

Retrospective Study, Oncology, Melanoma +7

Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019

Yasuhiro Nakamura, Jun Asai, Hiroshi Igaki et al. · The Journal of Dermatology · 2019 · 47 citations · Full text